Learn More
PURPOSE To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin(More)
INTRODUCTION Preterm infants are at increased risk of adverse neuro-developmental outcome (NDO). Cranial ultrasound has limited predictability. The aim of the study is to evaluate whether MRI done at(More)